SHYNDEC(SH:600420) Ge Long Hui A P P·2025-10-17 10:13Core Viewpoint - China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of Famotidine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval allows Famotidine injection to be used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor related conditions [1] - Famotidine is classified as a histamine H2 receptor antagonist [1] - The drug is indicated for various causes of gastric and duodenal mucosal erosion bleeding, excluding those related to tumors and esophageal or gastric varices [1]